UK pharmaceutical company GSK has announced spending of up to £130 million over five years to develop its manufacturing capabilities and other initiatives in Africa.
The announcement was made by Andrew Witty, the company’s chief executive, at the fifth EU-Africa Business Forum in Brussels on 31 March.
The company says it will be spending £25m on an R&D open lab for non-communicable diseases to allow scientists at the company’s Stevenage facility to work with researchers at centres across Africa. It will also be spending up to £100m on expanding existing manufacturing centres in Nigeria and Kenya and building up to five additional centres. Possible locations for those centres are in Rwanda, Ghana and Ethiopia, according to a statement from GSK.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.